GlycoMimetics (NASDAQ:GLYC) is set to announce its earnings results before the market opens on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.
GlycoMimetics (NASDAQ:GLYC) last announced its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.01. On average, analysts expect GlycoMimetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
GLYC stock traded down $0.06 during midday trading on Wednesday, reaching $9.13. 1,654 shares of the company’s stock traded hands, compared to its average volume of 613,785. The firm has a market capitalization of $396.40 million, a P/E ratio of -7.79 and a beta of 2.47. The firm has a fifty day simple moving average of $11.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 23.88 and a current ratio of 23.88. GlycoMimetics has a 52 week low of $8.29 and a 52 week high of $17.07.
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.
Read More: Marijuana Stocks
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.